Related Experiment Videos
Targeting ceramides in metabolic syndrome: recent advances and therapeutic opportunities
Jinrui Zhang1, Yiting Wang1, Xiaojun Liu2
1Department of Biochemistry and Molecular Biology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, #5 Dongdan santiao, Beijing, 100005, China.
Abstract:
Ceramides are bifunctional molecules that act as both structural constituents of cellular membranes and bioactive effectors in sphingolipid signaling. Their metabolic perturbation is a hallmark of metabolic syndrome, such as obesity, insulin resistance, type 2 diabetes mellitus, metabolic dysfunction-associated steatotic liver disease, and atherosclerosis. Among the numerous ceramide species, the long-chain species C16:0 and C18:0 have garnered particular attention due to their robust pathogenic roles and strong associations with human disease. This review critically examines the potential of ceramides as predictive biomarkers and provides novel translational perspectives for the clinical management of metabolic syndrome.